Publication: Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma
Loading...
Official URL
Full text at PDC
Publication Date
2017-02
Authors
Andrés Guerrero, Vanessa
Perucho González, Lucía
Morales Fernández, Laura
Sáenz Francés, Federico
Herrero Vanrell, Rocío
Pablo Júlvez, Luis
Polo Llorens, Vicente
Martínez de la Casa, Jose Maria
Konstas, Anastasios Georgios P.
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Healthcare
Citations
Exportar
Abstract
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments.
Description
Received: October 17, 2016 / Published online: December 20, 2016.
To view enhanced content for this article go to: http://www.medengine.com/Redeem/4237F06040074294.